Clinical Remission with Beclometasone/Formoterol/Glycopyrronium in Asthma: First Key Results from TriMaximize Study

Background: Clinical remission is a new goal in asthma management. Clinical remission has been extensively studied in patients requiring biologic treatment, however, it remains largely unexplored in patients with inhaled therapies only. In the TriMaximize study, we have investigated the clinical remission in moderate-to-severe asthma patients treated with extrafine formulation single-inhaler triple therapy consisting of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) in a real-world setting. Methods: TriMaximize is a multinational, observational study following asthma patients prescribed BDP/FF/G over one to three years. Patients were recruited at 165 sites across Germany, United Kingdom, Austria, Denmark, France, Spain, Poland and Italy. Data were analyzed descriptively. Two-component remission (2-CR) was defined by an absence of exacerbations and systemic corticosteroid use for at least one year, three-component remission (3-CR) was defined by an additional ACT score≥20 and four-component remission (4-CR) was defined by an additional lung function criterion (increase in FEV1≥100 ml compared with baseline). Results : A total of 1, 445 patients (62.8% female; mean age: 57.6 years) were included in the study. The majority (72.7%) had previously been treated with ICS/LABA (fixed or free) and 27.3% had received ICS/LABA/LAMA (fixed or free). One year after initiating extrafine BDP/FF/G therapy, 79.5% of patients achieved 2-CR. Furthermore, 45.6% of patients met the criteria for 3-CR, and 23.8% achieved 4-CR. In the following 2 years of treatment with BDP/FF/G, the proportion of patients with 2-CR increased to 84.1%, with 3-CR to 59.3% and with 4-CR to 34.7%. Conclusion: Clinical remission can be achieved in a large proportion of patients after 1 year of BDP/FF/G treatment in a real-world setting, and this proportion further increases in the following years. Publication History Article published online: 04 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany